Anna Chodos, MD, MPH, talks to Lawren VanDevrede, MD, PhD, Assistant Professor of Neurology at UCSF, as he explains developments the diagnostic criteria for Alzheimer’s disease, how to use and interpret biomarkers, and what the new monoclonal treatments for Alzheimer's disease mean for practice and our patients. 

The link to the 2024 guideline for Alzheimer’s disease diagnosis mentioned in the podcast is here.  

Click on this link, Understanding the New Diagnostics and Treatments in Alzheimer’s Disease Podcast Front Matter, for additional CE/CEU information. 

 After the completion of this activity, learners will be able to: 

1. Discuss past and current diagnostic criteria for a clinicopathological diagnosis of Alzheimer’s disease. 
2. Identify clinically available biomarker modalities for confirming Alzheimer’s and related neuropathologies. 
3. Explain currently implemented treatments for early stages of Alzheimer’s disease. 

Podcast listeners are eligible to receive FREE 0.50 AMA, AAPA, ANCC and AAFP credit. Please complete the survey below to claim credit. 

Evaluation survey: https://ucsf.co1.qualtrics.com/jfe/form/SV_25BRkZLg2AaQEN8 

Check out our training programs and resources at www.DementiaCareAware.org. Dementia Care Aware is by UCSF and sponsored by West Health. 

Facebook | LinkedIn | Youtube